{"id":5570,"date":"2023-10-24T14:51:12","date_gmt":"2023-10-24T14:51:12","guid":{"rendered":"https:\/\/aceoncology.org\/?post_type=ace_education&#038;p=5570"},"modified":"2023-12-18T11:10:48","modified_gmt":"2023-12-18T11:10:48","slug":"expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers","status":"publish","type":"ace_education","link":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/","title":{"rendered":"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<p>Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and\/or metastatic (LA\/m) urothelial cancer (UC) for several decades. With the evolving development of immunotherapy in the first-line (1L) setting, the standard management approach for LA\/m UC consisted of cisplatin-based CT in cisplatin eligible patients or carboplatin-based CT in cisplatin ineligible patients followed by maintenance avelumab (an anti-PD-L1 inhibitor) in those who do not have disease progression with 1L platinum-based CT.<\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>However, with the release of EV-302 and CheckMate-901 data during ESMO 2023, the landscape of 1L treatment becomes more competitive and complex. How can we access the new data? How can we strike a balance between efficacy and toxicity? How can we optimize decision-making regarding 1L treatment for both cisplatin-eligible and ineligible patients?<\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Let&#8217;s watch the recorded video on &#8216;Frequently Asked Questions (FAQs) for 1L Treatment Decision-making&#8217; to gain comprehensive insights from leading expert \u2013 Dr. Enrique Grande from MD Anderson Cancer Center Madrid.<\/p>\n\n\n\n<div style=\"height:13px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>This program is available with subtitles in the following languages:<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/05\/Screenshot-2023-05-10-144115.png\" alt=\"This image has an empty alt attribute; its file name is Screenshot-2023-05-10-144115.png\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Platinum-based chemotherapy (CT) has been the preferred [&hellip;]<\/p>\n","protected":false},"author":719,"featured_media":5288,"template":"","ace_education_category":[35],"ace_education_tag":[],"class_list":["post-5570","ace_education","type-ace_education","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer - ACE Oncology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"Platinum-based chemotherapy (CT) has been the preferred [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-18T11:10:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"721\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/\",\"name\":\"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"datePublished\":\"2023-10-24T14:51:12+00:00\",\"dateModified\":\"2023-12-18T11:10:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg\",\"width\":721,\"height\":450},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u5728\u7ebf\u6559\u80b2\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/education\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer - ACE Oncology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/","og_locale":"zh_CN","og_type":"article","og_title":"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer - ACE Oncology","og_description":"Platinum-based chemotherapy (CT) has been the preferred [&hellip;]","og_url":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/","og_site_name":"ACE Oncology","article_modified_time":"2023-12-18T11:10:48+00:00","og_image":[{"width":721,"height":450,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ace_oncology","twitter_misc":{"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/","url":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/","name":"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","datePublished":"2023-10-24T14:51:12+00:00","dateModified":"2023-12-18T11:10:48+00:00","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/04\/ExpertReviewUC_webthumbnail_721x450.jpg","width":721,"height":450},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/expert-interview-of-faqs-on-clinical-practice-in-urothelial-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"\u5728\u7ebf\u6559\u80b2","item":"https:\/\/aceoncology.org\/zh-hans\/education\/"},{"@type":"ListItem","position":3,"name":"Expert Interview 3: Frequently Asked Questions (FAQs) for First-Line (1L) Treatment Decision-making in Urothelial Cancer"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education\/5570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/ace_education"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/5288"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=5570"}],"wp:term":[{"taxonomy":"ace_education_category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_category?post=5570"},{"taxonomy":"ace_education_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_tag?post=5570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}